Annexon biosciences to present data highlighting novel approach to treating complement-driven diseases at upcoming medical meetings

Brisbane, calif., june 01, 2022 (globe newswire) -- annexon, inc. (nasdaq: annx), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that the company will present data from across its complement-targeted pipeline at several upcoming medical meetings.
ANNX Ratings Summary
ANNX Quant Ranking